SCHEMBL2974133

SCHEMBL2974133

Nc1ccc2nc(-c3ccccc3-c3ccccn3)[nH]c2c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 7/20 0.80
NPC1 O15118 7/20 0.80
RAB9A P51151 7/20 0.80
GAA P10253 5/20 0.80
SMN1; SMN2 Q16637 5/20 0.80
KDM4E B2RXH2 4/20 0.80
MAPT P10636 4/20 0.80
PKM P14618 4/20 0.80
HPGD P15428 3/20 0.80
LMNA P02545 3/20 0.80
TP53 P04637 1/20 0.80
NPSR1 Q6W5P4 1/20 0.80
L3MBTL1 Q9Y468 1/20 0.80
KMT2A Q03164 5/20 0.61
MEN1 O00255 4/20 0.61
POLB P06746 2/20 0.61
BLM P54132 2/20 0.61
UBE2N P61088 1/20 0.61
ALDH1A1 P00352 2/20 0.57
GLA P06280 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4371835 0.89 METAP2 (1.00) METAP2NPC1RAB9AGAASMN1; SMN2
SCHEMBL13973762 0.87 GAA (0.73) METAP2NPC1RAB9AGAASMN1; SMN2
SCHEMBL2978439 0.84 CBFB (0.80) METAP2NPC1RAB9AGAASMN1; SMN2
SCHEMBL4814803 0.84 METAP2 (0.84) METAP2NPC1RAB9AGAASMN1; SMN2
SCHEMBL13203406 0.83 NPC1 (0.76) METAP2NPC1RAB9AGAASMN1; SMN2
SCHEMBL2977111 0.82 GAA (0.60) METAP2NPC1RAB9AGAASMN1; SMN2
SCHEMBL13221240 0.80 GAA (0.77) METAP2NPC1RAB9AGAASMN1; SMN2
SCHEMBL11284879 0.80 GAA (0.73) METAP2NPC1RAB9AGAASMN1; SMN2
SCHEMBL13961658 0.79 KDM4E (0.76) METAP2NPC1RAB9AGAASMN1; SMN2
SCHEMBL2962892 0.78 NPC1 (0.58) METAP2NPC1RAB9AGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7777051-B2 Asymmetric benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2010-08-17 US disclosed
US-7777051-B2 Asymmetric benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2010-08-17 US disclosed
US-20050038067-A1 Asymmetric benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2005-02-17 US disclosed
WO-2005002503-A2 ASYMMETRIC BENZIMIDAZOLES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038067-A1 Asymmetric benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNJ1, KCNJ11 METAP2 3453/4885NPC1 709/4885RAB9A 3606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.